UNSPSC 51284704: Midecamycin

This classification denotes a leucomycin and macrolides with the molecular formula C41H67NO15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N34Z0Y5UH7, chemically known as leucomycin v, 3,4b-dipropanoate but generally known as midecamycin, which bears US NIH Compound Identifier 5382853. European Medicines Agency schedules midecamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08951MIG. The term MIDECAMYCIN is an International Non-Proprietary Name or INN.

Most nations schedule midecamycin under HS 29419000 and SITC 54139. As of Q4 2014, MIDECAMYCIN remains the US FDA Preferred Term for this commodity. SMILES: CCC(=O)OC1CC(=O)OC(CC=CC=CC(C(CC(C(C1OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)OC(=O)CC)(C)O)N(C)C)O)CC=O)C)O)C.

UNSPSC 51284704 Midecamycin is a Commodity code for a specific macrolide antibiotic pharmaceutical product, but state and local governments procure this category primarily through cooperative purchasing consortia and piggyback contracts rather than direct spot-market solicitations. The scope of work covers supply agreements for pharmaceutical inventory managed through group purchasing vehicles such as MMCAP Infuse, with state health departments and county community health agencies as typical buyers. Purchasing occurs through invitation-for-bid (IFB) processes that establish annual or multi-year supply contracts with fixed pricing and renewal options, often coupled with quarterly or as-needed delivery schedules to health facilities and community health buildings.

The recent opportunities block shows minimal direct activity under this specific code. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical supply contract via MMCAP Infuse to Chartwell Rx LLC in August 2026, but that solicitation covered Doxycycline Hyclate and Ciprofloxacin Hydrochloride — antibiotics with different active ingredients than Midecamycin — and is flagged as a completed award rather than an open opportunity. A Seminole County, Florida IFB (IFB60459723LAS) from June 2026 solicited Naloxone and Safe Drug Deactivation Systems for community health initiatives, which falls entirely outside the antibiotic pharmaceutical scope. The code shows no recent open solicitations specifically for Midecamycin supply. Activity in this category is driven by state health department procurement offices using cooperative purchasing vehicles and tends to cluster around antibiotic supply agreements, but the current opportunity pipeline at the Commodity level remains opaque from available state and local records.